Northwest Biotherapeutics Gains Confidence with New Data

First Berlin Equity Research has reiterated its BUY recommendation for Northwest Biotherapeutics Inc., emphasizing a target price of USD 1.00. The update follows the release of new analyses from Northwest's Phase 3 study of DCVax-L, an autologous dendritic cell vaccine aimed at treating glioblastoma (GBM). These analyses, presented at the 2026 British Neuro-Oncology Society meeting, highlight an improved survival benefit of 3.4-6.3 months compared to the previously reported 2.8 months.

The analyses used Propensity Score Matching and Inverse Probability Weighting methods to individual patient data, showcasing statistical significance. This development strengthens Northwest's UK Marketing Authorisation Application, particularly aligning with the MHRA's updated guidance on external control arms. Analyst Christian Orquera reaffirms the promising investment outlook with an upside potential exceeding 460%.